View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 10, 2011

MSDC Receives Funding for Alzheimer’s Drug Trial

Metabolic Solutions Development Company (MSDC) has received a $773,000 grant from the Alzheimer's Drug Discovery Foundation to conduct a Phase IIa trial of MSDC-0160, used for the treatment of metabolic diseases associated with altered mitochondrial function. The double-blind and, place

By cms admin

Metabolic Solutions Development Company (MSDC) has received a $773,000 grant from the Alzheimer’s Drug Discovery Foundation to conduct a Phase IIa trial of MSDC-0160, used for the treatment of metabolic diseases associated with altered mitochondrial function.

The double-blind and, placebo-controlled study will evaluate the safety profile and effects of the drug on brain glucose use in patients aged 55-85 with mild Alzheimer’s disease.

MSDC president and chief scientific officer Jerry Colca said the study will help determine if MSDC-0160 effects glucose use in specific regions of the brain and determine the feasibility of conducting future large-scale clinical studies in patients with mild Alzheimer’s disease.

The Alzheimer’s Drug Discovery Foundation granted MSDC $100,000 in 2009 for the pre-clinical study of the drug, which demonstrated positive effects in a mouse model of Alzheimer’s disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology